A personalized mRNA cancer therapy developed by Moderna and MSD Sharp & Dohme lowered the relative risk of relapse or death by 42 percent in patients with black skin cancer, according to BILD. The same trial found a 38 percent relative reduction in the risk of distant metastasis or death. The findings rest on data from more than 1,100 melanoma patients over the first two years after treatment and are due to be presented on Saturday at the congress of the European Society for Medical Oncology (ESMO) in Madrid.
Why it matters
The result is the first large-study demonstration that this tailored approach can work, BILD reports: analyze the tumor, build a vaccine to match it, then direct the immune system at the cancer cells. Unlike a conventional shot, the therapy is not identical for every patient. Each dose is adapted to the individual tumor by examining its characteristic mutations, and the resulting mRNA vaccine is meant to teach the immune system to recognize and attack cancer cells more effectively.
It is given alongside Keytruda (pembrolizumab), an established immunotherapy from MSD Sharp & Dohme that supports the body's own defenses against cancer. The combination is what the trial tested.
What the numbers actually mean
BILD stresses that the widely cited 42 percent does not mean 42 percent fewer patients died. It describes the relative reduction in the combined risk of suffering a relapse or dying. After two years, 82.2 percent of patients who received the personalized mRNA therapy plus Keytruda were still alive and free of relapse, compared with 70 percent in the group given Keytruda plus a placebo.
The metastasis figure follows the same logic. At two years, 88.5 percent of patients on the combination had no distant metastases, against 80.2 percent in the comparison group.
The treatment is not a general-purpose cancer vaccine. It targets people who already have melanoma. In the trial, participants had previously had their tumor removed surgically, and the therapy was intended to keep the disease from coming back.
Markets swing as detail arrives
Moderna and MSD Sharp & Dohme said in August that the large trial had succeeded, without releasing specific results at the time. Analysts had hoped the relapse risk would fall by at least 40 percent, BILD reports.
The stock reaction has been sharp in both directions. Before the August announcement, Moderna shares stood at about 63 dollars, according to BILD. They jumped 177 percent within a day and climbed further over the following weeks, at times trading near 245 dollars. On Thursday, after the detailed results became public, the stock fell as much as 25 percent to 181 dollars at one point.
Other German outlets covered the same swing. n-tv.de reported the vaccine's success alongside a 25 percent drop in Moderna's share price, while Handelsblatt described a slide of up to 26 percent following a data leak, and T-Online reported the stock shedding roughly a quarter of its value on the vaccine data.
There is still no confirmed start date in Germany. The therapy remains experimental and has not received regular approval.
For patients, BILD argues, the more consequential figure is the 42 percent relative reduction in relapse or death risk. If the benefit holds over the longer term and the therapy wins approval, the technology could mark a meaningful step toward cancer treatment designed around a single patient's tumor rather than the cancer type alone.
The coming ESMO presentation in Madrid will put the full dataset in front of oncologists, and the durability of the effect beyond two years is the number to watch.
